EMA Authorised: Samsca (tolvaptan) — Otsuka Pharmaceutical Netherlands B.V.

View source ↗

Summary

EMA authorised Samsca (tolvaptan) for the treatment of syndrome of inappropriate antidiuretic hormone secretion (SIADH), with Otsuka Pharmaceutical Netherlands …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hyponatremia
• Syndrome of Inappropriate Antidiuretic Hormone Secretion

Drugs mentioned

• Samsca (tolvaptan)

Snippet

Status: Authorised. Therapeutic area: Inappropriate ADH Syndrome. MAH: Otsuka Pharmaceutical Netherlands B.V.. Decision date: 13/02/2025